These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 30067444)

  • 41. DNA-PK inhibitor AZD7648 is a more portent radiosensitizer than PARP inhibitor Olaparib in BRCA1/2 deficient tumors.
    Wang T; Kyle AH; Baker JHE; Liu NA; Banáth JP; Teymori S; Minchinton AI
    DNA Repair (Amst); 2024 Jul; 139():103689. PubMed ID: 38749239
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Poly-ADP-Ribose Polymerase as a Therapeutic Target in Pediatric Diffuse Intrinsic Pontine Glioma and Pediatric High-Grade Astrocytoma.
    Chornenkyy Y; Agnihotri S; Yu M; Buczkowicz P; Rakopoulos P; Golbourn B; Garzia L; Siddaway R; Leung S; Rutka JT; Taylor MD; Dirks PB; Hawkins C
    Mol Cancer Ther; 2015 Nov; 14(11):2560-8. PubMed ID: 26351319
    [TBL] [Abstract][Full Text] [Related]  

  • 43. PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models.
    Pignochino Y; Capozzi F; D'Ambrosio L; Dell'Aglio C; Basiricò M; Canta M; Lorenzato A; Vignolo Lutati F; Aliberti S; Palesandro E; Boccone P; Galizia D; Miano S; Chiabotto G; Napione L; Gammaitoni L; Sangiolo D; Benassi MS; Pasini B; Chiorino G; Aglietta M; Grignani G
    Mol Cancer; 2017 Apr; 16(1):86. PubMed ID: 28454547
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Ganetespib overcomes resistance to PARP inhibitors in breast cancer by targeting core proteins in the DNA repair machinery.
    Jiang J; Lu Y; Li Z; Li L; Niu D; Xu W; Liu J; Fu L; Zhou Z; Gu Y; Xia F
    Invest New Drugs; 2017 Jun; 35(3):251-259. PubMed ID: 28111726
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Inhibition of Parp1 by BMN673 Effectively Sensitizes Cells to Radiotherapy by Upsetting the Balance of Repair Pathways Processing DNA Double-Strand Breaks.
    Soni A; Li F; Wang Y; Grabos M; Krieger LM; Chaudhary S; Hasan MSM; Ahmed M; Coleman CN; Teicher BA; Piekarz RL; Wang D; Iliakis GE
    Mol Cancer Ther; 2018 Oct; 17(10):2206-2216. PubMed ID: 29970481
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Combination effect of poly (ADP-ribose) polymerase inhibitor and DNA demethylating agents for treatment of epithelial ovarian cancer.
    Shim JI; Ryu JY; Jeong SY; Cho YJ; Choi JJ; Hwang JR; Choi JY; Sa JK; Lee JW
    Gynecol Oncol; 2022 May; 165(2):270-280. PubMed ID: 35305818
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Poly(ADP-ribose) polymerase-1 regulates the mechanism of irradiation-induced CNE-2 human nasopharyngeal carcinoma cell autophagy and inhibition of autophagy contributes to the radiation sensitization of CNE-2 cells.
    Zhou ZR; Zhu XD; Zhao W; Qu S; Su F; Huang ST; Ma JL; Li XY
    Oncol Rep; 2013 Jun; 29(6):2498-506. PubMed ID: 23563481
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Radiosensitization by PARP Inhibition in DNA Repair Proficient and Deficient Tumor Cells: Proliferative Recovery in Senescent Cells.
    Alotaibi M; Sharma K; Saleh T; Povirk LF; Hendrickson EA; Gewirtz DA
    Radiat Res; 2016 Mar; 185(3):229-45. PubMed ID: 26934368
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effects of Combined Treatment with Ionizing Radiation and the PARP Inhibitor Olaparib in BRCA Mutant and Wild Type Patient-Derived Pancreatic Cancer Xenografts.
    Lohse I; Kumareswaran R; Cao P; Pitcher B; Gallinger S; Bristow RG; Hedley DW
    PLoS One; 2016; 11(12):e0167272. PubMed ID: 28033382
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Inhibition of PARP-1 by olaparib (AZD2281) increases the radiosensitivity of a lung tumor xenograft.
    Senra JM; Telfer BA; Cherry KE; McCrudden CM; Hirst DG; O'Connor MJ; Wedge SR; Stratford IJ
    Mol Cancer Ther; 2011 Oct; 10(10):1949-58. PubMed ID: 21825006
    [TBL] [Abstract][Full Text] [Related]  

  • 51. PARP inhibitor veliparib and HDAC inhibitor SAHA synergistically co-target the UHRF1/BRCA1 DNA damage repair complex in prostate cancer cells.
    Yin L; Liu Y; Peng Y; Peng Y; Yu X; Gao Y; Yuan B; Zhu Q; Cao T; He L; Gong Z; Sun L; Fan X; Li X
    J Exp Clin Cancer Res; 2018 Jul; 37(1):153. PubMed ID: 30012171
    [TBL] [Abstract][Full Text] [Related]  

  • 52. MAPK4 deletion enhances radiation effects and triggers synergistic lethality with simultaneous PARP1 inhibition in cervical cancer.
    Tian S; Lou L; Tian M; Lu G; Tian J; Chen X
    J Exp Clin Cancer Res; 2020 Jul; 39(1):143. PubMed ID: 32711558
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Mechanistic Dissection of PARP1 Trapping and the Impact on In Vivo Tolerability and Efficacy of PARP Inhibitors.
    Hopkins TA; Shi Y; Rodriguez LE; Solomon LR; Donawho CK; DiGiammarino EL; Panchal SC; Wilsbacher JL; Gao W; Olson AM; Stolarik DF; Osterling DJ; Johnson EF; Maag D
    Mol Cancer Res; 2015 Nov; 13(11):1465-77. PubMed ID: 26217019
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Trastuzumab-Resistant HER2
    Wielgos ME; Zhang Z; Rajbhandari R; Cooper TS; Zeng L; Forero A; Esteva FJ; Osborne CK; Schiff R; LoBuglio AF; Nozell SE; Yang ES
    Mol Cancer Ther; 2018 May; 17(5):921-930. PubMed ID: 29592880
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A functional ex vivo assay to detect PARP1-EJ repair and radiosensitization by PARP-inhibitor in prostate cancer.
    Köcher S; Beyer B; Lange T; Nordquist L; Volquardsen J; Burdak-Rothkamm S; Schlomm T; Petersen C; Rothkamm K; Mansour WY
    Int J Cancer; 2019 Apr; 144(7):1685-1696. PubMed ID: 30478958
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Poly (ADP-ribose) polymerases inhibitor, Zj6413, as a potential therapeutic agent against breast cancer.
    Zhou Q; Ji M; Zhou J; Jin J; Xue N; Chen J; Xu B; Chen X
    Biochem Pharmacol; 2016 May; 107():29-40. PubMed ID: 26920250
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Radiosensitization effect of poly(ADP-ribose) polymerase inhibition in cells exposed to low and high liner energy transfer radiation.
    Hirai T; Shirai H; Fujimori H; Okayasu R; Sasai K; Masutani M
    Cancer Sci; 2012 Jun; 103(6):1045-50. PubMed ID: 22404155
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Targeted radiosensitization of ETS fusion-positive prostate cancer through PARP1 inhibition.
    Han S; Brenner JC; Sabolch A; Jackson W; Speers C; Wilder-Romans K; Knudsen KE; Lawrence TS; Chinnaiyan AM; Feng FY
    Neoplasia; 2013 Oct; 15(10):1207-17. PubMed ID: 24204199
    [TBL] [Abstract][Full Text] [Related]  

  • 59. New insights into PARP inhibitors' effect on cell cycle and homology-directed DNA damage repair.
    Jelinic P; Levine DA
    Mol Cancer Ther; 2014 Jun; 13(6):1645-54. PubMed ID: 24694947
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Targeting PARP proteins in acute leukemia: DNA damage response inhibition and therapeutic strategies.
    Padella A; Ghelli Luserna Di Rorà A; Marconi G; Ghetti M; Martinelli G; Simonetti G
    J Hematol Oncol; 2022 Jan; 15(1):10. PubMed ID: 35065680
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.